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Identity 
Hugo: EBAG9 
Other names: EB9; PDAF; RCAS1 
Location: 8q23.2 
DNA/RNA 
Description 
The EBAG9 gene contains 7 exons and 6 introns. It 
was predicted to span over approximately 24.6 kb of 
the genomic DNA with mRNA size approximately 
1182 bp. The exon 3 was the smallest at 79 bp; the 
other exons ranged from 92-720 bp. The EBAG9 was 
isolated from MCF-7, human breast cancer cell library 
and it has been reported identical with RCAS1 
(receptor-binding cancer antigen expressed on SiSo 
cells) gene from human uterine adenocarcinoma cell 
line. 
Transcription 
The EBAG9 mRNA is up-regulated by estrogen in 
MCF-7 cells and its promoter responds to estrogen 
through the complete palindromic estrogen responsive 
element (ERE) that was located in the 5'-up stream 
region of the gene. 
Pseudogene 
One pseudogene located in chromosome 10 associated 
with RCAS1/EBAG9. 
Protein 
Description 
The EBAG9/RCAS1 consists of 213 amino acids (aa) 
corresponding to a molecular weight of 24.4 kDa. The  
EBAG9/RCAS1 has an N-terminal trans-membrane 
segment (8-27 aa) and a coiled-coil structure in the C-
terminal portion (179-206 aa), indicating that the 
EBAG9/RCAS1 is a type II membrane protein able to 
form oligomers through the coiled-coil structure, which 
is expressed on the surfaces of human cancer cells. 
Expression 
The EBAG9/RCAS1 mRNA is expressed in ovary, 
testis, prostate, thymus, muscle, and heart. At the 
protein level the EBAG9/RCAS1 not detected in 
normal ovary tissues or any of the other above. Neither 
mRNA nor protein was detected in small intestine, 
colon, lymph node or peripheral blood lymphocytes. 
Localisation 
Mainly in the golgi, membrane and cytoplasm of 
cancer tissues, but its expression is very low or hardly 
detected in normal tissues. 
Function 
The biological functions of the EBAG9/RCAS1 
secreted by non-cancerous tissues remain unknown. 
In cancer cells, the EBAG9/RCAS1 is a ligand for a 
putative receptor present on various human cell lines 
and normal peripheral lymphocytes such as T-, B- and 
natural killer (NK)-cells. The expression of this 
receptor is enhanced by activation of these 
lymphocytes. The EBAG9/RCAS1 acts to inhibit the 
growth of receptor-binding cells and induced apoptotic 
cell death. Over-expression of the EBAG9/RCAS1 is 
known to inhibit the growth and induced apoptosis of 
immune cells. As the results, cancer cells might evade 
immune surveillance by expressing the 
EBAG9/RCAS1 and inducing the apoptosis of the 
EBAG9/RCAS1 receptor-positive immune cells. 
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Homology 
Mouse and human EBAG9/RCAS1 shows a high 
degree of homology at the amino acid level (98%). 
Mouse (Mus musculus) ebag9 gene spans about 30 kb 
in genomic DNA and consists of 7 exons. Dog (Canis 
familiaris) EBAG9/RCAS1 also shows highly 
homologues to human (96,2%) and to mouse (96,7%). 
For chimpanzee (Pan troglodytes) 100%, rat (Rattus 
norvegicus) 94% and chicken-ebag9 (Gallus gallus) 
91%. 
Mutations 
Germinal 
Not known in Homo sapiens. 
Somatic 
Not known in Homo sapiens. 
Implicated in 
Immunity 
Note: During pregnancy, EBAG9/RCAS1 may play a 
role in the down-regulation of the maternal immune 
response and may participate in the initiation of the 
labor. In the healthy women, higher EBAG9/RCAS1 
expression was observed in the periovulatory and the 
secretory menstrual cycle phases than in the 
proliferation phase. The changes in EBAG9/RCAS1 
expression were combined with significant differences 
in the number of immune cells and their activity. It 
suggested that EBAG9/RCAS1 endometrial expression 
may favor the coexistence of active lymphocytes and 
endometrial cells. 
Disease 
The elevated serum level of EBAG9/RCAS1 reported 
to be associated with a poor immunological prognosis 
in HIV-1-infected patients, and also associated with the 
apoptosis of CD4+ T cells in HIV infection. In 
addition, the induction and secretion of 
EBAG9/RCAS1 in HIV-Trans-acting transcriptional 
activator-stimulated CD4+ T cells and monocytes 
suggested that EBAG9/RCAS1 may involved in the 
CD4+ T cell apoptosis observed in HIV-1 infection 
along with FasL and TRAIL. 
Malignancy. 
Disease 
The EBAG9/RCAS1 reported to be over-expressed in 
many human cancers. Among them: breast, female-
genital, gastrointestinal, blood, lung, pancreas, liver, 
renal, billiary-tract, hepatic, prostate, thyroid, gall 
bladder, and brain cancer. 
Prognosis 
The EBAG9/RCAS1 over-expression could be used as 
a predictor of poor prognosis in malignant diseases. 
Oncogenesis 
The EBAG9/RCAS1 plays a role in the immune escape 
of cancer cells. The EBAG9/RCAS1 could help cancer 
cells to survive and avoid immunosurveillance. This 
gene over-expression might cause progression, invasion 
and metastasis. The EBAG9 acts as one of the estrogen 
responsive genes in estrogen receptor-positive tumors 
and mediate estrogen function. Overall, the 
EBAG9/RCAS1 has an etiological role in the 
development and progression of cancer cells. 
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